earnings
confidence high
sentiment negative
materiality 0.70
AbbVie expects Q2 2025 acquired IPR&D expense of $823M, lowers adjusted EPS guide
AbbVie Inc.
2025-Q2 EPS
reported $1.24
vs consensus $2.94
▼ miss
(-57.9%)
- Acquired IPR&D and milestones expense of $823M pre-tax in Q2 2025 reduces GAAP and adjusted EPS by $0.42.
- Full-year 2025 adjusted diluted EPS guidance range lowered to $11.67-$11.87 from $12.09-$12.29.
- Q2 2025 adjusted diluted EPS guidance range now $2.84-$2.88 versus prior $3.26-$3.30.
- Guidance excludes any acquired IPR&D expense beyond Q2 2025 due to forecasting uncertainty.
- Q2 2025 results are preliminary and subject to financial statement closing procedures.
item 2.02item 9.01